Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
2.6.2024 15:30:00 EEST | Business Wire | Press release
Denodo, a leader in data management is opening their new Middle East regional head office in Riyadh, Kingdom of Saudi Arabia (KSA) today. To inaugurate the office opening, Denodo is launching their first “Denodo Data Day” with Her Highness Dr. Shaikha Dheya Bint Ebrahim Al Khalifa and delegates from Google Cloud, among others, as guest speakers. The new office will support new and existing Denodo customers and partners in the Middle East, providing them with direct access to the company’s experts in logical data management and AI-supported data solutions. This regional expansion is a testament to Denodo’s growing business and its customers in the region.
"We are thrilled to expand our presence in the Middle East with the opening of our new office in Riyadh, a city known for its rapid growth and innovation," said Ángel Viña, CEO and founder at Denodo. "Riyadh is host to a growing number of companies and government agencies, particularly in the technology, finance, and energy sectors – including the ambitious NEOM City. This new office will enable us to better serve our customers in the Middle East, providing them with our 'fearless data' approach to logical data management and the cutting-edge solutions they need to stay ahead in today's competitive market."
Denodo has made significant investments in AI and GenAI, which supports the Kingdom’s Vision 2030’s AI goals of making Saudi Arabia an international AI hub. Saudi Arabia is investing heavily in AI to diversify its economy. PwC recently published estimates that AI will contribute more than $135 billion to Saudi Arabia’s economy by 2030, which would lessen its reliance on revenue from oil. The Kingdom’s National Strategy aims for a global AI ranking of 15 by 2030. Recently, Saudi Arabia gained the top spot for AI government strategy. However, data management remains a hurdle. Traditional methods are complex and slow, hindering businesses seeking AI's potential in areas like customer experience.
“Saudi Arabia is the largest economy in the Middle East, and it’s going through an amazing period of growth and change,” said Gabriele Obino, regional vice president and general manager, Middle East, Denodo. “Denodo is a pioneer in logical data management, and we are offering local and regional organizations, in various industries including aviation, healthcare and Government, the opportunity to start or continue their digital transformations to modern cloud and GenAI-based data solutions.”
By fostering strong collaboration with key technology providers and systems integrators, such as the global cloud hyperscaler Google Cloud, Denodo demonstrates that its customers in the Middle East have access to the most innovative and comprehensive data solutions available, empowering them to make informed, data-driven decisions to help them stay ahead in today's competitive landscape.
Niall McDonagh, director, EMEA Public Sector, Google Cloud, emphasized the unique position of Google Cloud in Saudi Arabia: “As the only cloud provider with a dedicated region in Saudi Arabia, Google Cloud is uniquely positioned to support the digital transformation needs of this vibrant market. Our partnership with Denodo for the inaugural Denodo Data Day in Riyadh is a pivotal moment for us to showcase how our cloud solutions, coupled with Denodo’s logical data management technology, can drive significant advancements in key industries such as finance, healthcare, government, and education. We are also excited to highlight the capabilities of our Google Cloud Center of Excellence, which provides strategic guidance and cloud technology expertise.”
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading logical data management platform for delivering data in the language of business, at the speed of business, for all data-related initiatives across the organization. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across enterprises in 30+ industries all over the world have received payback in less than six months. For more information, visit denodo.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240602513059/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Completes Acquisition of Moody’s Regulatory Reporting & Asset and Liability Management (ALM) Solutions5.5.2026 09:00:00 EEST | Press release
Regnology, a global provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the completion of its acquisition of Moody’s Regulatory Reporting & ALM Solutions business. The transaction expands Regnology’s solution portfolio with Moody’s comprehensive capabilities covering Basel III compliance, IFRS 9 impairment, large‑bank asset and liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting. The transaction closes at a pivotal inflection point. Financial institutions face intensifying regulatory scrutiny, growing data complexity, and rising expectations for governance and auditability, while advances in artificial intelligence are creating new opportunities to modernize control frameworks and operating models. Regnology is responding by accelerating its Straight-Through Reporting (STR) vision and leveraging the combined capabilities of the transaction to deliver more resilient, transparen
AB InBev Reports First Quarter 2026 Results5.5.2026 08:02:00 EEST | Press release
Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504526109/en/ Regulated information1 “Cheers to beer - the strength of the category and the consistent execution of our consumer-centric strategy drove continued momentum across our footprint. We are investing behind our megabrands and innovations to lead and grow the category. With strong execution by our teams and major moments of celebration ahead, we are well positioned for 2026.” – Michel Doukeris, CEO, AB InBev Revenue +5.8% Revenue increased by 5.8% with revenue per hl growth of 4.5%. Reported revenue increased by 12.0% to 15 267 million USD, positively impacted by currency translation. 8.2% increase in combined revenues of megabrands, led by Corona, which grew by 16% outside of its home market. 27% increase in revenue of no-alcohol beer. 37% increase in revenue of Beyond Beer. 55% increase in Gross Mer
Kerecis Drives the Fish-Skin Conversation at Leading European Wound Conference - EWMA-DEWU 20264.5.2026 21:25:00 EEST | Press release
Kerecis, the company pioneering the use of sustainably sourced intact fish skin in cellular therapy and tissue regeneration, will play a prominent scientific and educational role at the EWMA‑DEWU 2026 Conference, taking place May 6–8 at the Messe & Congress Centrum Bremen in Bremen, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504487743/en/ MariCell® Solid This year, The European Wound Management Association's (EWMA) meeting is held in conjunction with the Deutscher Wundkongress (DEWU); combining two major wound-care congresses into a single forum for scientific exchange, education, and clinical discussion. At this year’s conference, Kerecis will highlight growing clinical experience with intact fish‑skin grafts across a broad range of wound indications, supported by two Kerecis‑led scientific symposia, multiple oral and poster presentations, and direct engagement with clinicians at Booth D30, located adjacent
Printing the Future of Medicine: CTIBIOTECH™ Announces $27 Million Investment to Launch U.S. Operations at the SelectUSA Investment Summit4.5.2026 21:00:00 EEST | Press release
CTIBIOTECH™, a pioneering Contract Research, Development, and Manufacturing Organization (CRDMO) and global leader in 3D bioprinting of human tissues, today officially announces the launch of its North American subsidiary, CTIBIOTECH USA™. The official launch took place today at the prestigious SelectUSA Investment Summit in Washington, D.C. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504107996/en/ From Biopsy to Breakthrough, CTIBIOTECH USA™'s Vision for Precision Medicine Operating from its new United States base in the thriving life sciences “Cellicon Valley” hub of Philadelphia, Pennsylvania, in association with BioLabs for Advanced Therapeutics, CTIBIOTECH USA™ will provide the company's proprietary human cell and tissue bioassays and New Approach Methods (NAMs) directly to North American pharmaceutical, biomedical, and dermatocosmetics markets. By producing and supplying these cutting-edge human bioassays domesti
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 18:16:00 EEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom